Global Bacterial Conjunctivitis Treatment Market was valued at US $ XX Mn and expected to grow at XX% Compound Annual Growth Rate (CAGR) over 2018 to 2024.
Market Outline: Bacterial Conjunctivitis Treatment Market
Conjunctivitis refers to the inflammation of membrane which covers the outmost layer of the eye. In U.S. it is called as pink eye. Conjunctivitis usually caused by the infection, allergy or driven by the irritant. However, infectious conjunctivitis particularly bacterial conjunctivitis affects most of the patients. Bacterial conjunctivitis is highly contagious disease which spread through sneezing, coughing or direct contact with the bacteria. It will not cause any problem if diagnosed and treated in early stages. But if it left untreated may lead to the vision loss or serious eye problems.
Market Dynamics: Bacterial Conjunctivitis Treatment Market
Global bacterial conjunctivitis market is preliminarily driven by the high incidence rates of bacterial conjunctivitis worldwide coupled with the rise in awareness related to the health and funded eye checkup campaign by the governments of different nations around the world. In addition, rise in investments for development of new drugs, pipeline drus, increase in the public and government spending on health expected to boost the market growth over the forecast period. However, side effects associated with the antibiotics, high cost of drug discovery & development and stringent regulatory approval polices are expected to hamper the market growth over the forecast period.
Market Scope: Bacterial Conjunctivitis Treatment Market
Global bacterial conjunctivitis treatment market is segmented based on the type, application, end user and geography
Based on dosage form, the market is segmented into the following:
- Eye Drops
- Gels & Creams
- Tablets and Capsules
Based on drug class, the market is segmented into the following:
- Anti-Inflammatory Agents
Based on distribution channel, market is segmented into following:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Based on region, Market is segmented into
- North America
- Latin America
- Asia Pacific
- Middle East and Africa (MEA)
Regional Analysis: Bacterial Conjunctivitis Treatment Market
Geographically, global corticosteroids Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America bacterial conjunctivitis treatment market projected to have the significant growth rate owing to the high incidence rates of bacterial conjunctivitis in the region. According to a recent survey published in the JAMA (Journal of the American Medical Association) over 50% of the conjunctivitis in U.S. are bacterial origin. In addition, well established healthcare infrastructure, rise in awareness related to the health, government support in rising awareness related to available alternatives for treatment projected to boost the regional market furthermore. Asia Pacific bacterial conjunctivitis treatment market expected to grow at notable rates owing to the significant increase in the healthcare spending, medical infrastructure especially in developing countries such as India and China. Furthermore, low cost of production, huge and patient base attracting the multinational players to expand into Asia Pacific region. Europe bacterial conjunctivitis market expected to grow at notable rates owing to the presence of key market players and rise in awareness.
Competition Assessment: Bacterial Conjunctivitis Treatment Market
Some of the players in the global corticosteroids Market include:
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Merck & Co., Inc. (U.S.)
- Pfizer Inc. (U.S.)
- Perrigo Company plc (U.S.)
- Santen Pharmaceutical Co., Ltd. (Japan)
- Valeant Pharmaceuticals International, Inc. (U.S.)
- Hoffmann-La Roche AG (Switzerland)
- Lupin Ltd. (India)
- Shire Plc (Ireland)
Notable Market Developments: Bacterial Conjunctivitis Treatment Market
- In May 2018, Lupin ltd. has launched generic version of moxifloxacin hydrochloride ophthalmic solution in U.S. market.
- In April 2017, Shire has initiated the phase 3 clinical trials for SHP 650 for infectious conjunctivitis in adult and children